Green whistle gets the green light for preparation of US clinical trial
14 August 2023Find out more
Our Strategic Vision
The Company’s strategic focus is to accelerate penetration of acute pain portfolio through expansion into new customer channels and geography, and to grow its Respiratory segment through market share gains. The clinical hold lifted by the FDA without any additional conditions has allowed commencement of Phase III clinical trials for our acute pain portfolio, which has opened the door for longer-term growth in the USA.
Receive investor news
Keep abreast of company news, events and investor email alerts
Half Year Results
Advancing our strategic agenda and the next phase of growthAccess here